Department of Obstetrics, Gynecology & Reproductive Sciences

Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Ovarian Cancer



Vaagn Andikyan, MD

Assistant Professor Obstetrics, Gynecology and Reproductive Sciences Yale School of Medicine

April 1, 2021 • 4:00-5:00 pm

Dial-In: 203.432.9666; Meeting ID: 201.194.039; https://zoom.us/j/201194039

There is no corporate support for this activity.

Course Director/Host: Lubna Pal, MBBS, FRCOG, MS, FACOG

ACCREDITATION:

The Yale School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

TARGET AUDIENCE:

ObGyn attending physicians, house staff/fellows, medical students, nurses, PA's, community Ob/Gyn's, residents, midwives, nurses and researchers.

NEEDS ASSESSMENT:

Ovarian cancer treatment is not optimal in modern era. About 80% of patients experience recurrence during disease course. New treatment modalities are in high demand. HIPEC has been used in the treatment of peritoneal surface malignancies. Here we report on our experience and on current status of HIPEC in the treatment of ovarian cancer.

LEARNING OBJECTIVES:

At the end of this presentation, attendees will be able to:

- 1. Understand rational and mechanism of action of HIPEC;
- 2. Identify indication, contraindication and side effects of HIPEC in the treatment of ovarian cancer.
- 3. Become familiar with current status of HIPEC in the treatment of ovarian cancer.

DESIGNATION STATEMENT

The Yale School of Medicine designates this live activity for 1 AMA PRA Category 1 Credit(s)™. Physicians should only claim the credit commensurate with the extent of their participation in the activity.

FACULTY DISCLOSURES:

Course Director: Lubna Pal, MD

Flo Health, Consultant AMAG Advisory Board, Member Abbott Advisory Board, Member

Speaker: Vaagn Andikyan, MD

It is the policy of Yale School of Medicine, Continuing Medical Education, to ensure balance, independence, objectivity and scientific rigor in all its educational programs. All faculty participating as speakers in these programs are required to disclose any relevant financial relationship(s) they (or spouse or partner) have with a commercial interest that benefits the individual in any financial amount that has occurred within the past 12 months; and the opportunity to affect the content of CME about the products or services of the commercial interests. The Center for Continuing Medical Education will ensure that any conflicts of interest are resolved before the educational activity occurs.

